Sparteine oxidation is practically abolished in quinidine-treated patients

British Journal of Clinical Pharmacology
R BrinnS V Otton

Abstract

In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.

References

Mar 1, 1985·British Journal of Clinical Pharmacology·R V LewisH F Woods
Jan 1, 1986·European Journal of Clinical Pharmacology·T LeemannU A Meyer
Jan 1, 1985·European Journal of Clinical Pharmacology·M Eichelbaum, N M Woolhouse
Jul 15, 1985·Biochemical Pharmacology·C von BahrF Sjöqvist
Nov 1, 1985·Acta Pharmacologica Et Toxicologica·K BrøsenL F Gram
Jan 1, 1982·European Journal of Drug Metabolism and Pharmacokinetics·P DayerJ Fabre
Jan 1, 1984·European Journal of Clinical Pharmacology·A Küpfer, R Preisig
Dec 1, 1984·Clinical Pharmacology and Therapeutics·P J WedlundR A Branch
Jul 1, 1984·Clinical Pharmacology and Therapeutics·T C RaghuramA J Wood
Mar 1, 1980·Clinical Pharmacokinetics·H R OchsE Woo
Jan 1, 1982·Clinical Pharmacology and Therapeutics·A VinksW Kalow
Dec 16, 1982·The New England Journal of Medicine·M S LennardH F Woods

❮ Previous
Next ❯

Citations

Jan 1, 1989·European Journal of Clinical Pharmacology·K Brøsen, L F Gram
Jan 1, 1989·European Journal of Clinical Pharmacology·K Brøsen, L F Gram
Jan 1, 1992·European Journal of Clinical Pharmacology·A MunafoJ Biollaz
Oct 1, 1989·European Journal of Drug Metabolism and Pharmacokinetics·C KöppelI Arndt
Jan 1, 1990·Pharmacology & Therapeutics·U A MeyerU M Zanger
Jun 1, 1990·Trends in Pharmacological Sciences·D D Breimer, J H Schellens
Feb 1, 1990·British Journal of Clinical Pharmacology·K BrøsenL F Gram
Mar 1, 1990·British Journal of Clinical Pharmacology·M D NielsenL F Gram
Mar 1, 1992·British Journal of Clinical Pharmacology·U M BirgersdotterD M Roden
Jan 1, 1991·Fundamental & Clinical Pharmacology·G Alván
Feb 1, 1989·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·G MuralidharanT Inaba
Jan 19, 2016·Pharmacogenomics·Rashmi R ShahRobert L Smith
Apr 17, 2007·Journal of the Neurological Sciences·Ariel Miller, Hillel Panitch
Mar 18, 2004·British Journal of Clinical Pharmacology·Benjamin J L DaviesBenedetta C Sallustio
May 25, 2010·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·C KragelundL A Torpet
Aug 1, 1989·British Journal of Clinical Pharmacology·J O AtibaG R Wilkinson
Feb 1, 1989·British Journal of Clinical Pharmacology·L F GramE Zarifian
Apr 1, 1987·Pharmacology & Toxicology·K BrøsenL Bertilsson
Feb 6, 2004·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·Lis Andersen TorpetBirgitte Nauntofte
May 2, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Masakatsu KotsumaKenji Nishimura
Jan 1, 1988·Acta Psychiatrica Scandinavica. Supplementum·L F Gram
Oct 6, 1999·British Journal of Clinical Pharmacology·R Abdul ManapA H Morice
Oct 1, 1986·British Journal of Clinical Pharmacology·K Brøsen
Feb 15, 2000·British Journal of Clinical Pharmacology·P DalénL Bertilsson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.